OxVax Company
OxVax focused on the development of an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumor cancers.
Technology:
Dendritic Cells
Industry:
Dendritic Cells
Headquarters:
Oxford, Oxfordshire, United Kingdom
Founded Date:
2021-01-01
Funding Status:
Seed
Investors Number:
2
Total Funding:
12500000
Last Funding Date:
2021-04-21
Last Funding Type:
Seed
Register and Claim Ownership